NEW YORK (GenomeWeb) – Enzo Biochem reported after the close of the market on Monday that its second quarter revenues rose 3 percent year over year, thanks almost entirely to a 4 percent increase in its clinical laboratory service revenues.

For the three months ended Jan. 31, the firm reported total revenues of $27.0 million, up from $26.3 million in Q2 2017.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The UK's Nuffield Council on Bioethics says genetically modifying human embryos could be morally permissible, according to the Guardian.

A new Nature Biotechnology paper reports that CRISPR-Cas9 gene editing can lead to large deletions or complex rearrangements that could be pathogenic.

The Wall Street Journal likens a prototype developed by Synthetic Genomics to a "biological fax machine."

In PNAS this week: strategy for reactivating Rett syndrome-linked MECP2, small molecules able to suppress Staphylococcus aureus virulence, and more.